<DOC>
	<DOCNO>NCT02411448</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy ramucirumab combination erlotinib compare placebo combination erlotinib participant stage IV non small cell lung cancer ( NSCLC ) harbor activate epidermal growth factor receptor ( EGFR ) mutation ( Del19 L858R ) . Safety tolerability ramucirumab combination erlotinib assess first portion ( Part A ) proceed second portion study ( Part B ) .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Combination With Erlotinib Participants With EGFR Mutation-Positive Metastatic NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Cytologically histologically confirm diagnosis Stage IV NSCLC define American Joint Committee Cancer Staging Criteria Lung Cancer ( AJCC 7th edition 2009 ) . Eligible firstline treatment erlotinib base documented evidence tumor harbor activate EGFR mutation ( Example 19 del L858R ) . Mandatory provision adequate archive stage IV NSCLC tissue sample . At least one measurable lesion . Life expectancy least 3 month . Known T790M EGFR mutation . Known leptomeningeal carcinomatosis , uncontrolled/unstable spinal cord compression , brain metastasis . Serious illness medical condition . Ongoing treatment CYP3A4 inducer strong/moderate inhibitor . Ongoing therapy nonsteroidal antiinflammatory drug 2 month . History gross hemoptysis . Significant bleeding disorder . Radiologically document evidence major blood vessel invasion encasement cancer . Radiographic evidence intratumor cavitation . History gastrointestinal perforation within last 6 month . History bowel obstruction , inflammatory enteropathy extensive intestinal resection . History arterial thrombotic event within 6 month prior enrollment . The participant know significant ophthalmologic abnormality surface eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>